Public source
Reviewed 29 Jul 2026
Completeness Good (44%)
ArteraAI Prostate Biopsy Assay
ArteraAIThe ArteraAI Prostate Test can be used for patients across all NCCN risk groups, with 10-year risk of distant metastasis (DM) and prostate cancer-specific mortality (PCSM) reported and can be used to assess how aggressive the cancer is.
For lower-risk patients, the ArteraAI Prostate Test provides a binary indication of distant metastasis risk, indicating if the patient’s risk may warrant earlier treatment.
For intermediate-risk patients, the ArteraAI Prostate Test can be used to predict if there will be a therapeutic benefit from adding ST-ADT to radiation therapy.
For higher-risk patients, the ArteraAI Prostate Test can help inform if adding abiraterone to LT-ADT and radiation therapy may be of benefit.
Supported by 10 papers
General Information
Product name
Company
Modality
Main task
Subspeciality
Organ/Specimen source
Not specified
Disease targeted
Specimen type
Staining
Stain subtype
Not specified
Regulatory Information
Verified by Health AI Register
Pathway:
In Vitro Diagnostic Regulation (IVDR)
Class:
Class C
Not verified by Health AI Register
Scanner Brands Certified for Use (CE-IVD)
Not specified
Scanner Models Certified for Use (CE-IVD)
Not specified
Other certifications
Not specified
Evidence & Research
Peer-Reviewed Papers
Cost-effectiveness of an artificial intelligence predictive model for guiding androgen deprivation therapy in intermediate-risk prostate cancer
JNCI Cancer Spectrum · Apr 2026
External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol
The Lancet Digital Health · Jun 2025
Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials
JCO Clinical Cancer Informatics · May 2025
Validation of a Digital Pathology–Based Multimodal Artificial Intelligence Biomarker in a Prospective, Real-World Prostate Cancer Cohort Treated with Prostatectomy
Clinical Cancer Research · Feb 2025
An Artificial Intelligence–Digital Pathology Algorithm Predicts Survival After Radical Prostatectomy From the Prostate, Lung, Colorectal, and Ovarian Cancer Trial
Journal of Urology · Feb 2025
Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer
JCO Precision Oncology · Jan 2025
Digital Pathology–based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer
European Urology Oncology · Dec 2024
Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer
Radiotherapy and Oncology · Nov 2024
Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology
JCO Precision Oncology · Oct 2024
External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial
European Urology Oncology · Feb 2024
Technical Specifications
Patient population age
Not specified
Input
Not specified
Input format
Not specified
Output
Not specified
Output format
Not specified
Integration
Not specified
Deployment
Trigger for analysis
Not specified
Processing time
Not specified
Population
Viewer systems
Not specified
Market Presence
On market since
Not specified
AI Platforms
Resellers
Not specified
Countries present
Not specified
Paying clinical customers
Not specified
Research/test users
Not specified
Pricing Information
Pricing model
Based on
Not specified
Source: Public | First published: Apr 21, 2026 | Last updated: Jul 29, 2026